

# Christopher J Molloy

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8600534/publications.pdf>

Version: 2024-02-01

42  
papers

2,363  
citations

304602

22  
h-index

289141

40  
g-index

42  
all docs

42  
docs citations

42  
times ranked

2116  
citing authors

#	ARTICLE	IF	CITATIONS
1	PDGF induction of tyrosine phosphorylation of GTPase activating protein. <i>Nature</i> , 1989, 342, 711-714.	13.7	502
2	Discovery and Cocrystal Structure of Benzodiazepinedione HDM2 Antagonists That Activate p53 in Cells. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 909-912.	2.9	436
3	Benzodiazepinedione inhibitors of the Hdm2:p53 complex suppress human tumor cell proliferation in vitro and sensitize tumors to doxorubicin in vivo. <i>Molecular Cancer Therapeutics</i> , 2006, 5, 160-169.	1.9	175
4	Development of a highly efficient expression cDNA cloning system: application to oncogene isolation.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1991, 88, 5167-5171.	3.3	148
5	JNJ-28312141, a novel orally active colony-stimulating factor-1 receptor/FMS-related receptor tyrosine kinase-3 receptor tyrosine kinase inhibitor with potential utility in solid tumors, bone metastases, and acute myeloid leukemia. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 3151-3161.	1.9	103
6	Autocrine mechanism for v-sis transformation requires cell surface localization of internally activated growth factor receptors.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1989, 86, 8063-8067.	3.3	98
7	Synthesis of thiophene-2-carboxamidines containing 2-amino-thiazoles and their biological evaluation as urokinase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2001, 11, 915-918.	1.0	92
8	Epiregulin is a potent vascular smooth muscle cell-derived mitogen induced by angiotensin II, endothelin-1, and thrombin. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1999, 96, 1633-1638.	3.3	74
9	Endothelin-1 and angiotensin-II stimulate delayed mitogenesis in cultured rat aortic smooth muscle cells: evidence for common signaling mechanisms. <i>Molecular Endocrinology</i> , 1994, 8, 148-158.	3.7	58
10	Molecular characterization of angiotensin II type II receptors in rat pheochromocytoma cells. <i>Peptides</i> , 1992, 13, 499-508.	1.2	54
11	Orally Active Endothelin Receptor Antagonist BMS-182874 Suppresses Neointimal Development in Balloon-Injured Rat Carotid Arteries. <i>Journal of Cardiovascular Pharmacology</i> , 1995, 26, 908-915.	0.8	50
12	Activin A and TGF- $\beta$ 2 Stimulate Phosphorylation of Focal Adhesion Proteins and Cytoskeletal Reorganization in Rat Aortic Smooth Muscle Cells. <i>Experimental Cell Research</i> , 1999, 251, 194-202.	1.2	47
13	Synthesis and evaluation of novel 3,4,6-substituted 2-quinolones as FMS kinase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 2097-2102.	1.0	46
14	Discovery of novel FMS kinase inhibitors as anti-inflammatory agents. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 1642-1648.	1.0	40
15	Effect of retinoid deficiency on keratin expression in mouse bladder. <i>Experimental and Molecular Pathology</i> , 1988, 49, 128-140.	0.9	34
16	Epidermal Growth Factor Activates Phosphoinositide Turnover and Protein Kinase C in BALB/MK Keratinocytes. <i>Molecular Endocrinology</i> , 1988, 2, 799-805.	3.7	34
17	Novel cardiovascular actions of the activins. <i>Journal of Endocrinology</i> , 1999, 161, 179-185.	1.2	31
18	Carboxylic acid bioisosteres acylsulfonamides, acylsulfamides, and sulfonylureas as novel antagonists of the CXCR2 receptor. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 1926-1930.	1.0	30

#	ARTICLE	IF	CITATIONS
19	Pharmacokinetic and Pharmacodynamic Modeling of Pegylated Thrombopoietin Mimetic Peptide (PEG-TPOM) After Single Intravenous Dose Administration in Healthy Subjects. <i>Journal of Clinical Pharmacology</i> , 2009, 49, 336-350.	1.0	30
20	Optimization of a Potent Class of Arylamide Colony-Stimulating Factor-1 Receptor Inhibitors Leading to Anti-inflammatory Clinical Candidate 4-Cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[(dimethylamino)acetyl]-4-piperidinyl]phenyl]-1H-imidazole-2-carboxamide (JN-28312141). <i>Journal of Medicinal Chemistry</i> , 2011, 54, 7860-7883.	2.9	30
21	Structure-based optimization of a potent class of arylamide FMS inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 3632-3637.	1.0	29
22	Design and Synthesis of 4,5-Disubstituted-thiophene-2-amidines as Potent Urokinase Inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2002, 12, 491-495.	1.0	26
23	Keratin polypeptide expression in mouse epidermis and cultured epidermal cells. <i>Differentiation</i> , 1988, 37, 86-97.	1.0	22
24	Effects of thrombin receptor activating peptide on phosphoinositide hydrolysis and protein kinase C activation in cultured rat aortic smooth muscle cells: evidence for a tethered-ligand activation of smooth muscle cell thrombin receptors. <i>Biochemical Pharmacology</i> , 1993, 45, 1577-1582.	2.0	19
25	Pharmacodynamics and Pharmacokinetics of the Novel Thrombopoietin Mimetic Peptide RWJ-800088 in Humans. <i>Clinical Pharmacology and Therapeutics</i> , 2008, 84, 481-487.	2.3	18
26	Expression of protein kinase C I in NIH 3T3 cells increases its growth response to specific activators. <i>FEBS Letters</i> , 1990, 260, 281-284.	1.3	16
27	Structure-Based design, synthesis and sAR of a novel series of thiopheneamidine urokinase plasminogen activator inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2001, 11, 1379-1382.	1.0	15
28	A novel series of arylsulfonylthiophene-2-carboxamide inhibitors of the complement component C1s. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2006, 16, 2200-2204.	1.0	15
29	Biphenylsulfonyl-thiophene-carboxamide inhibitors of the complement component C1s. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 1603-1606.	1.0	15
30	Alterations in the expression of specific epidermal keratin markers in the hairless mouse by the topical application of the tumor promoters 2,3,7,8-tetrachlorodibenzo-p-dioxin and the phorbol ester 12-O-tetradecanoylphorbol-13-acetate. <i>Carcinogenesis</i> , 1987, 8, 1193-1199.	1.3	14
31	Reducing ion channel activity in a series of 4-heterocyclic arylamide FMS inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 3925-3929.	1.0	11
32	ROLE OF MATRIX METALLOPROTEINASES AND PLASMINOGEN ACTIVATORS IN CANCER INVASION AND METASTASIS: THERAPEUTIC STRATEGIES. , 2002, , 91-122.		10
33	The discovery of novel cyclohexylamide CCR2 antagonists. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 7496-7501.	1.0	10
34	Design and synthesis of polyethylene glycol-modified biphenylsulfonyl-thiophene-carboxamide inhibitors of the complement component C1s. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 5303-5307.	1.0	7
35	Alterations in Mouse Epidermal Keratin Production Induced by Dietary Vitamin A Deficiency. <i>Annals of the New York Academy of Sciences</i> , 1985, 455, 739-740.	1.8	6
36	Uneven distribution of protein kinase C-? and -? isozymes in human sarcomas and carcinomas. <i>Journal of Cellular Physiology</i> , 1994, 159, 434-440.	2.0	5

#	ARTICLE	IF	CITATIONS
37	Novel signal transduction targets in cardiovascular disease: Role of platelet-derived growth factor in vascular smooth muscle cell proliferation. <i>Drug Development Research</i> , 1993, 29, 148-157.	1.4	3
38	Fighting pulmonary fibrosis: new science brings new therapeutic opportunities. <i>Drug Discovery Today: Therapeutic Strategies</i> , 2004, 1, 361-368.	0.5	3
39	Enhancement of kinase selectivity in a potent class of arylamide FMS inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 6363-6369.	1.0	3
40	Altered expression of a mouse epidermal cytoskeletal protein is a sensitive marker for proliferation induced by tumor promoters. <i>Carcinogenesis</i> , 1992, 13, 963-968.	1.3	2
41	A functional radioreceptor assay of alpha-V-beta-3 ( $\alpha_5\beta_3$ ) inhibitors in plasma: Application as an ex vivo pharmacodynamic model. <i>Journal of Proteomics</i> , 2005, 65, 107-120.	2.4	1
42	EGF Triggers a Similar Signalling Cascade in Different Cell Types Overexpressing the EGF Receptor. , 1990, , 39-47.		1